NovoCure Ltd (NAS:NVCR)
$ 23.7 0.95 (4.18%) Market Cap: 2.55 Bil Enterprise Value: 2.17 Bil PE Ratio: 0 PB Ratio: 7.10 GF Score: 60/100

Novocure Ltd at Wells Fargo Healthcare Conference Transcript

Sep 07, 2023 / 04:45PM GMT
Release Date Price: $20 (-3.33%)
Lawrence H. Biegelsen
Wells Fargo Securities, LLC, Research Division - Senior Medical Device Equity Research Analyst

Good afternoon, everyone. I'm Larry Biegelsen, the medical device analyst at Wells Fargo. It's my pleasure to host this session with NovoCure. With us, we have Bill Doyle, Executive Chairman; Ashley Cordova, the CFO. In terms of format, it's going to be fireside chat. If anybody has a question, please raise your hand, we'll come around. Bill and Ashley, thanks so much for being here.

William F. Doyle
NovoCure Limited - Executive Chairman

Thank you, Larry. Thanks for having us.

Ashley Cordova
NovoCure Limited - CFO

Thanks for having us, Larry.

Questions & Answers

Lawrence H. Biegelsen
Wells Fargo Securities, LLC, Research Division - Senior Medical Device Equity Research Analyst

Of course. So let's start with the INNOVATE-3 top line results that you guys released, I don't know, about a week ago. Bill, maybe just provide us with your perspective

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot